The agreement covers several fully human anti-HCV antibody clones identified from patients who have recovered from HCV infections.
The Ben Gurion University of the Nege department of microbiology, immunology and genetics professor and vice chair Dr Leslie Lobel said, "We are pleased to be collaborating with Sorrento to develop our fully human anti-HCV antibody clones into potential anti-HCV therapeutics."
Under the deal, Sorrento is responsible for the development of potential therapeutic and/or prophylactic anti-HCV antibody products.
The collaborative effort uses the strengths of each organization to create a product opportunity consisting of therapeutic and/or prophylactic agents against HCV infections.
Sorrento president and CEO Henry Ji said, "We are excited to be working with Dr. Lobel to add a program targeting HCV to our existing portfolio of therapeutic antibodies for the prevention and/or treatment of major infectious diseases."